<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=384506&amp;fmt=gif">
Skip to content
    April 30, 2011

    FDA Panel Unanimously Approves Two New Hep C drugs



    Amid all the angst regarding the high costs of drug discovery, it is refreshing to see two new drugs for Hepatitis C approved by FDA advisory panels. In the past two days the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) unanimously approved ™ (boceprevir)and Vertex’s telaprevir. (Disclaimer: CDD CEO Barry Bunin has been a Vertex Shareholder since the telepravir phase 2 results were announced).

    As a community of scientists, clinicians, executives, regulators, patients, and people, we can take a moment to smile and appreciate the progress. The prognosis is now brighter for those with Hepatitis C. And given the strong pipelines, new targets, and large need, it seems that the Hep C combination therapies will only get better in the near future.






    This blog is authored by members of the CDD Vault community. CDD Vault is a hosted drug discovery informatics platform that securely manages both private and external biological and chemical data. It provides core functionality including chemical registration, structure activity relationship, chemical inventory, and electronic lab notebook capabilities!

    CDD Vault: Drug Discovery Informatics your whole project team will embrace!

    Tag(s): CDD Blog

    Other posts you might be interested in

    View All Posts
    CDD Blog
    9 min   March 26, 2024
    Drug Discovery Industry Roundup with Barry Bunin — March 26, 2024
    Read More
    CDD Blog
    2 min   March 26, 2024
    Recorded Webinar: Trends & Better Practices for the Use of Gen AI & LLMs
    Read More
    CDD Blog
    2 min   March 22, 2024
    Recorded Webinar: Interdisciplinary Pathways in Medicine- from Neurodegenerative to Oncology Disease Research and Drug Discovery
    Read More